Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

OBJECTIVE: Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks or who switched from reference infliximab (Remic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B., Radominski, Sebastiao C., Kameda, Hideto, Kivitz, Alan J., Tee, Michael, Cronenberger, Carol, Zhang, Min, Hackley, Sarah, Rehman, Muhammad I., von Richter, Oliver, Alten, Rieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113200/
https://www.ncbi.nlm.nih.gov/pubmed/31939063
http://dx.doi.org/10.1007/s40259-019-00403-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113200/
https://www.ncbi.nlm.nih.gov/pubmed/31939063
http://dx.doi.org/10.1007/s40259-019-00403-z

Ejemplares similares